Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Nov. 30, 2021 |
Nov. 30, 2020 |
Nov. 30, 2021 |
Nov. 30, 2020 |
|
| Research and development expenses | $ 6,835,304 | $ 6,274,283 | $ 20,757,937 | $ 10,504,093 |
| Restricted Stock Units | ||||
| Antidilutive securities | 4,014,928 | 4,171,609 | ||
| Warrants | ||||
| Antidilutive securities | 11,659,418 | 4,693,802 | ||
| Stock Options [Member] | ||||
| Antidilutive securities | 1,570,000 | 1,587,081 | ||